$10m boost for Calypte HIV urine test launch
This article was originally published in Clinica
Executive Summary
Calypte Biomedical has raised more than $10 million in a private placement which will enable the firm to proceed with the manufacture of its urine-based test for HIV-1. It will also use the money to undertake clinical trials for a home collection version of the test.